You just read:

Boehringer Ingelheim Announces Nintedanib Expanded Access Program (EAP) for Patients with Idiopathic Pulmonary Fibrosis

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Jun 24, 2014, 11:47 ET